Lexpos News

Almost three-quarters of community pharmacy owners have completed the 2026/27 Community Pharmacy Assurance Framework (CPAF) screening questionnaire, with one week left to complete. We encourage pharmacy owners who have not yet responded to the questionnaire to ensure they do so by Friday, 31st July 2026. Completing the screening questionnaire is a Terms of Service requirement and significantly [...]

The post CPAF Screening Questionnaire 2026/27 – one week left to complete appeared first on Community Pharmacy England.

Following the launch of the Meningococcal B (MenB) Vaccination Service this week, Community Pharmacy England has been working with NHS England to monitor its early progress and address teething issues.  NHS England has already taken action to support pharmacies in response to the concerns we raised around the initial ordering and allocation process. NHS England is continuing to review these processes daily.  Pharmacy owners will need to manage their vaccination capacity and [...]

The post MenB vac update: reminders and FAQs appeared first on Community Pharmacy England.

The NHS Business Services Authority (NHSBSA) produces a quarterly newsletter called “Hints & Tips”. The latest edition (Issue 64) contains some useful information and advice on: Last chance to submit your Pharmacy Quality Scheme aspiration payment declaration – deadline Tuesday 28 July 2026 2026/27 Drug Tariff updates Community Pharmacy NHS Meningococcal B Vaccination Service – [...]

The post NHSBSA ‘Hints & Tips’ – Issue 64 appeared first on Community Pharmacy England.

Department of Health and Social Care (DHSC) has issued a medicine supply notification for Nifedipine 10mg, 20mg, 30mg and 60mg modified-release tablets. MSN/2026/033 Tier 2 – medium impact Date of issue: 23 July 2026 Various brands and strengths of nifedipine modified-release tablets are experiencing supply issues: Tensipine® MR 10 and 20 tablets will be out [...]

The post Medicine Supply Notification: Nifedipine 10mg, 20mg, 30mg and 60mg modified-release tablets appeared first on Community Pharmacy England.

MHRA Class 4 Medicines Defect Notification: Tuzulby prolonged-release chewable tablets (Neuraxpharm UK Ltd) Drug alert number: EL(26)A/36 Date issued: 23 July 2026 Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged release 20mg, 30mg and [...]

The post MHRA Class 4 Medicines Defect Notification: Tuzulby prolonged-release chewable tablets (Neuraxpharm UK Ltd) appeared first on Community Pharmacy England.